UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1166-12
Program Prior Authorization/Notification
Medication Praluent® (alirocumab)*
P&T Approval Date 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 6/2021, 6/2022, 6/2023,
2/2024, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Praluent (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor
antibody indicated:
• To reduce the risk of myocardial infarction, stroke, and unstable angina requiring
hospitalization in adults with established cardiovascular disease.
• As adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol
(LDL-C)-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary
hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.
• As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial
hypercholesterolemia (HoFH) to reduce LDL-C.
• As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years
and older with HeFH to reduce LDL-C.
2. Coverage Criteriaa:
A. Hyperlipidemia
1. Initial Authorization
a. Praluent* will be approved based on all of the following criteria:
(1) One of the following diagnoses:
(a) Primary hyperlipidemia
-OR-
(b) Heterozygous familial hypercholesterolemia (HeFH)
-OR-
(c) Atherosclerotic cardiovascular disease (ASCVD) (e.g., acute coronary
syndromes, history of myocardial infarction, stable or unstable angina,
coronary or other arterial revascularization, stroke, transient ischemic attack, or
peripheral arterial disease presumed to be of atherosclerotic origin)
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Not used in combination with another proprotein convertase subtilisin/kexin type
9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]
-AND-
(3) Not used in combination with Leqvio (inclisiran)
Authorization will be issued for 12 months
2. Reauthorization
a. Praluent* will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Praluent* therapy
-AND-
(2) Not used in combination with another proprotein convertase subtilisin/kexin type
9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]
-AND-
(3) Not used in combination with Leqvio (inclisiran)
Authorization will be issued for 12 months
B. Homozygous Familial Hypercholesterolemia
1. Initial Authorization
a. Praluent* will be approved based on all of the following criteria:
(1) Diagnosis of homozygous familial hypercholesterolemia
-AND-
(2) Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL
apheresis)
-AND-
(3) Not used in combination with another proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitor [e.g., Repatha (evolocumab)]
-AND-
(4) Not used in combination with Juxtapid (lomitapide)
Authorization will be issued for 12 months
© 2025 UnitedHealthcare Services, Inc.
2
2. Reauthorization
a. Praluent* will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Praluent* therapy
-AND-
(2) Not used in combination with another proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitor
-AND-
(3) Not used in combination with Juxtapid (lomitapide)
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
*Praluent is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to
plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Medical Necessity, Supply Limits and Step Therapy may be in place.
4. References:
1. Praluent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; March 2024.
Program Prior Authorization/Notification – Praluent® (alirocumab)
Change Control
8/2015 New program.
7/2016 Annual Review. Updated reference.
7/2017 Annual review with no changes to coverage criteria. Updated reference.
7/2018 Annual review with no changes to coverage criteria. Updated reference.
7/2019 Annual review. Updated background and criteria aligning with new label
for the prevention of cardiovascular events in patients with established
ASCVD and in patients with primary hyperlipidemia alone or in
combination with other therapies. Updated reference.
7/2020 Annual review with no changes to coverage intent. Changed initial
authorization to 12 months. Updated reference.
6/2021 Annual review. Updated background and added criteria to align with new
label for homozygous familial hypercholesterolemia. Added Praluent
exclusion statement. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3
6/2022 Annual review with no changes to coverage criteria. Added state mandate
footnote and updated exclusion statement.
6/2023 Annual review. Updated background. Added criteria that Praluent is not
to be used in combination with Leqvio.
2/2024 Simplified reauthorization criteria.
5/2024 Updated background to align with new label for pediatric patients aged 8
years and older with HeFH. Updated reference.
5/2025 Annual review. Removed diet requirement.
© 2025 UnitedHealthcare Services, Inc.
4